## **Core Concept**
The question tests knowledge of DPP-4 inhibitors, a class of oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. DPP-4 inhibitors work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the inactivation of incretin hormones. This leads to an increase in insulin secretion and a decrease in glucagon levels.

## **Why the Correct Answer is Right**
The correct answer, , is a DPP-4 inhibitor that is primarily excreted via the liver and bile, making it a safer option for patients with renal failure. Unlike other DPP-4 inhibitors that are primarily excreted by the kidneys, does not require dose adjustment in patients with mild to moderate renal impairment.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is primarily excreted by the kidneys and requires dose adjustment in patients with renal impairment, making it less suitable for patients with renal failure.
* **Option B:** is also primarily excreted by the kidneys and has dose adjustment recommendations for patients with renal impairment.
* **Option D:** is excreted by both the kidneys and liver, but dose adjustments are recommended for patients with moderate to severe renal impairment.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that is the DPP-4 inhibitor of choice in patients with renal failure due to its primarily hepatic excretion and lack of requirement for dose adjustment in renal impairment.

## **Correct Answer:** .